ban on semaglutide A South African court has ordered pharmacy group iDexis to stop selling semaglutide-based medicines. The ruling follows a legal challenge by Novo Nordisk, maker of Ozempic and Wegovy. Novo alleged the company Compounded Semaglutide & Tirzepatide 2025:
Description
GLP-1 receptor agonists (such as semaglutide) and dual agonists like tirzepatide have transformed obesity and diabetes management
Hundreds of patients have reported experiencing severe side effects, including Ozempic vomiting
Book your personalized consultation today.
And the number may keep growing
Today we announced positive topline results from the first Phase 1b clinical trial of elecoglipron conducted in China in adults living with obesity/overweight, with or without type 2 diabetes
